UNICYCIVE THERAPEUTICS, INC. Cash and Restricted Cash
UNICYCIVE THERAPEUTICS, INC. (UNCY) had Cash and Restricted Cash of $44.19 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $44.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37.37M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29.20M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42.70M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $44.19M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $37.37M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $29.20M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $42.70M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $22.33M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $19.77M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $26.14M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $32.35M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $41.78M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $48.93M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $9.70M 10-K · filed 2026-03-30 |
| 2023-09-30 | $14.35M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $18.82M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $24.33M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $455.00K 10-K · filed 2025-03-31 |
| 2022-09-30 | $7.01M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $10.57M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $13.62M 10-Q · filed 2023-05-16 |
| 2021-12-31 | $16.58M 10-K · filed 2024-03-28 |
| 2021-09-30 | $18.01M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-15 |
| 2021-03-31 | $147.00K 10-Q · filed 2022-05-12 |
| 2020-09-30 | $63.00K 10-Q · filed 2021-11-12 |
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-16 |
| 2019-12-31 | $15.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |